PubMed Health⌕ Search

Biomedical subjects

B Perpoint

Publications and source records attributed to B Perpoint.

34 records · Page 2Linked to original sources

[Self-medication in rheumatologic consultation. Apropos of a study on 895 patients].

A study was undertaken to evaluate the use of self-administered medication in 895 patients with rheumatologic disorders by all of the 18 rheumatologists practicing in one region (the southern portion of the Loire Department and all of the Haute-Loire Department) over a six-day period. It was noted that 445 out of 895 patients (49.72 percent) reported taking one or several medications other than those prescribed during the previous 3 month period before their office visit. Self-administered medications were taken at least weekly in 53.5 percent of cases and at least monthly in 83,7 percent. Most often one or two medications were involved (60.9 and 25.6 percent respectively). Age, profession, the presence or absence of psychiatric disturbances, the duration of the doctor-patient relationship, as well as the patient's specific rheumatologic problem seemed to be influencing factors. Aspirin or other analgesics comprised 53.1 percent of the medication taken, whereas other non-steroidal antiinflammatory agents comprised only 2.3 percent. No steroids were self-administered. There are multiple potential side effects with self-administered drugs: therapy can be poorly suited for the illness in question, it may delay diagnosis and the beginning of effective therapy, there can be increased iatrogenic risk due to inadequate therapy, and unnecessary expense. Drugs used as self-administered medications originate most often from previous medical prescriptions which may or may not have been prescribed for the patient's same medical problem (34.4 percent), and most medication used was bought without needing a prescription (52.4 percent). Prevention, therefore, requires that potential consumers of self-administered drugs be educated concerning these problems, as well as health professionals, the pharmaceutical industry, and concerned government agencies.

Adolescent↗

[Nycthemeral change in the anticoagulant effect of heparin given at a constant rate by the intravenous route].

Six subjects with venous thromboembolism volunteered for this prospective study. Heparin was administrated intravenously at a constant rate with an infusion pump. The activated partial thromboplastin time (A.P.T.T.) and thrombin time (T.T.) were measured every 4 hrs. for 48 hrs. These coagulation tests exhibited a nycthemeral variation with a large amplitude which was reproducible from one day to the next and statistically validated by the cosinor method (p less than 0.001). All patients had a nocturnal peak of A.P.T.T. and T.T. on both days. In four patients this peak for A.P.T.T. exceeded the upper desired limit.

Aged↗

[Chronokinetics of ketoprofen administered orally and by continuous venous infusion].

The aim of the study was to evaluate a possible chronokinetic phenomenon of ketoprofen administered orally and by continuous intravenous infusion. In the first part of the study, ketoprofen was administered orally to 8 healthy male volunteers aged between 25 and 45 years, at a dose of 2 X 50 mg at 7:00 a.m. (time I), 1:00 p.m. (time II), 7:00 p.m. (time III) and 1:00 a.m. (time IV), on the same day of the week at an interval of 2 weeks, during the first three months of the year. The order of administration was randomised, each subject acted as his own control and received ketoprofen at the four times mentioned above. A total of 14 venous blood samples were taken over 12 hours. The results indicate that the maximal serum concentration (Cmax) was significantly higher at time I (13.4 +/- 14.1) than at times II, III and IV (6.9 +/- 1.1, 7.2 +/- 0.7, 6.4 +/- 0.5 mg/l) (p less than 0.01). The time required to reach this concentration (Tmax) was significantly longer for time IV (135.0 +/- 16,8) than for times I, II and III (73,1 +/- 14.1, 75,0 +/- 16.6; 82.5 +/- 12.7 minutes) (p less than 0.05). The excretion half-life (t 1/2B) was significantly longer for time IV (4.3 +/- 0.6) than for times II and III (2.8 +/- 0.5, 2.5 +/- 0.2 hours) (p less than 0.05). Statistically significant differences were also observed in the area under the curve measured at midday (AUC 12) and in the total clearance (CIT) for the various sample times.(ABSTRACT TRUNCATED AT 250 WORDS)

Administration, Oral↗

[Macroglossia in apparently primary amyloidosis].

The authors report a case of apparently primary amyloidosis in which macroglossia was the clinical presentation, confirmed by lingual biopsy. They take advantage of this case to review the therapeutic possibilities, though stating that from a stomatological standpoint there is virtually nothing available.

Aged↗

[Influence of tobacco on the serum levels and pharmacokinetics of phenylbutazone and oxyphenbutazone].

The serum levels of a number of drugs are reduced by smoking. The authors wanted to see whether this phenomenon occurred with phenylbutazone. With this objective, they compared the changes in serum levels of phenylbutazone and oxyphenbutazone, the hydroxylated metabolite of phenylbutazone, during ten days of administration, in 9 smokers and in 6 non-smokers. Blood samples were taken every day at 8:00 a.m. and the PB and OPB were assayed by high performance liquid chromatography. The comparison of the mean serum levels of PB in smokers and non-smokers revealed a statistically significant reduction (p less than or equal to 0.05) of this level in the smoker, between D5 and D10. Comparison of the mean serum levels of OPB in smokers and non-smokers revealed a statistically significant reduction of this level in the smoker, but only on days 9 and 10. When we compare these results with those reported in the literature for other drugs, it would appear that tobacco smoke accelerates the metabolism of phenylbutazone and oxyphenbutazone by a mechanism of enzyme induction. It is proposed that the therapeutic activity of phenylbutazone is reduced in the smoker, but this has not been confirmed by a reliable clinical evaluation in this initial study.

Adult↗

[Value of anti hemolysin and anti-gammahemolysin assays for the diagnosis of staphylococcal infections, particularly of osteoarthritis (author's transl)].

The authors report the results of more than twelve years' personal research on the value of anti-alphahemolysin (AASTL) and antigammahemolysin (AGSTL) assays for the diagnosis of staphylococcal infections, and particularly of osteoarthritis. Among 574 controls, AASTL levels exceeded 2 IU in only 14 subjects (11 of these, levels were between 2 and 3 IU). Levels less than, or equal to, 2 IU were therefore considered normal. This is consistent with previously published data. In 144 staphylococcal infections, confirmed by bacteriology, an increase in AASTL was found in 95 of all cases (65.9%) and in 54 of the 76 osteoarthritis' (71%). Similarly, AGSTL titres, which were under 1/160 (upper normal limit) in 138 controls, were increased in 35 patients with unequivocal staphylococcal infections (61.4%), and in 25 of 36 patients with osteoarthritis (69.4%). These results show that AASTL assay is reliable and often abnormal. However, assay of both hemolysins yields even better results. This dual assay was performed in 57 patients with staphylococcal infection. One hemolysin at least was increased in 47 patients (82.4%). This represents additional positivity in 15.7% of patients when compared to AASTL assay alone, and in 21% when compared to AGSTL assay alone. The high level of positive results with dual assay is even more striking when only staphylococcal osteoarthritis is considered: one or both hemolysins were increased in 91.1% of these patients (31/34).

Antibodies, Bacterial↗

[Acro-osteolysis in leprosy. Apropos of 19 personal cases].

Using their own personal series of 19 cases of leprosy complicated by massive osteolysis (AO), along with a comparison of these cases with data from previously published reports, the authors review the principal clinical and radiological findings of these manifestations which are not observed except in cases of leprosy where neuropathy is present, even though other factors (perforating plantar ulcers, poor hygiene, traumatisms) may play a contributing role independent of possible interference from non specific osteoarthritis or Hansen's bacilla, itself. After reviewing other causes of massive osteolysis and discussing the pathogeny of these manifestations during leprosy, the authors refer to the various therapies which can prevent or stabilize osteolysis or aid the patient to better tolerate its manifestations.

Adolescent↗

Intraperitoneal chemohyperthermia for peritoneal carcinomatosis: original modeling, clinical tolerance and results study about 30 patients.

BACKGROUND/AIMS: The authors' objective is to report their experience of the intraperitoneal chemohyperthermia after a thermal modeling study which has allowed the optimization the intraperitoneal chemohyperthermia circuit and its running parameters and to evaluate the intraperitoneal chemohyperthermia tolerance. Intraperitoneal chemohyperthermia is considered more and more as an interesting therapeutic option in cases of some abdominal carcinomatosis, particularly of digestive origin. However, the main technical problem of this treatment is the homogenization of the temperature distribution in the abdominal cavity. METHODOLOGY: A thermal modeling has allowed us to finalize a reliable and well-tolerated intraperitoneal chemohyperthermia technique. The achievement of a physical model of the abdomen has allowed us to make an experimental study of the temperature distribution in a given liquid volume. Two steps were carried out. The first step was the characterization of the model with a thermal study carried out on the physical model and which has led to dynamic data about the heat balance leading to a knowledge model. The second step was the identification of a theoretical model of the thermal behavior which would correlate best with the experimental data. Between January 1995 and January 1998, 30 patients with peritoneal carcinomatosis were studied. Twenty-six patients underwent maximal cytoreductive surgery with abdominal evisceration, intraperitoneal chemohyperthermia. Intraperitoneal chemohyperthermia was carried out for 1 hour, at 42 degrees C, with a flow rate of 0.9 L/min in the 30 patients. The thermal modeling has shown the main purpose of a high flow rate of 0.9 L/min in the homogenization of temperature distribution. RESULTS: The 2 steps are shown to converge. This coherency between the 2 models proves that the thermal aspects of the process have been properly identified. Our initial results have shown that intraperitoneal chemohyperthermia was properly tolerated. Major intraoperative complications occurred for 1 patient. CONCLUSIONS: The experimental study with thermal modeling results should help to optimize the intraperitoneal chemohyperthermia circuit and its running parameters for human treatment, with an acceptable morbidity in 30 patients.

Adolescent↗

[Value of the peroperative association of echography, extemporaneous cytology and immediately available insulin blood levels of the portal vein. Apropos of 2 cases of insulinoma].

The authors report two cases of insulinoma managed by per-operative ultrasound and cytology, together with immediate portal vein insulin levels. They stress the value of these per-operative exploratory techniques which reduce the number of pre-operative invasive examinations while ensuring a greater efficacy in the localization and treatment of these tumors.

Adenoma, Islet Cell↗